KDDF-201402-01

Harvard researchers have discovered that intranasal insulin (INI) may help prevent cognitive decline in type 2 diabetes patients by improving memory network efficiency in the brain.

Eisai presented Phase 1/2 data on E2814, an anti-tau drug, showing reduced levels of disease biomarkers in participants with mild to moderate genetic Alzheimer’s.

Eisai's E2814, an anti-tau drug, showed promise in reducing disease biomarkers in a Phase 1 trial involving participants with genetic Alzheimer's, warranting further studies.

Enhanced titration dosing of donanemab in the TRAILBLAZER-ALZ-6 trial significantly reduced the frequency and severity of ARIA-E in early symptomatic Alzheimer's disease patients.